-
Gadolinium-Based Contrast Agents: Gadolinium Retention Higher For Linear Gadolinium Agents Than Macrocyclic Agents
Gadolinium Retention Can Cause Various Medical Problems With General Diagnosis Label Of Gadolinium Deposition Disease (Posted by Tom Lamb at DrugInjuryWatch.com) There are two types of gadolinium based contrast agents (GBCAs): linear and…
-
Rexulti Warnings For Compulsive Behavior And Impulse Control Problems Added To Drug Label
FDA: Patients Using Rexulti At Risk For Experiencing Intense Urges For Gambling And Inability To Control Conduct (Posted by Tom Lamb at DrugInjuryWatch.com) Rexulti® (brexpiprazole) was initially approved by the FDA in…
-
Gadolinium Retention Warnings Added To Drug Labels For Gadolinium Contrast Agents Used During MRI / MRA
Label Changes Announced By FDA In December 2017 Finally Approved For Magnevist, Omniscan, And Other GBCAs In April 2018 (Posted by Tom Lamb at DrugInjuryWatch.com) Gadolinium based contrast agents (GBCAs) are substances…
-
Some MRI Contrast Agents Containing Gadolinium Can Cause Problems Ranging From “Brain Fog” To Permanent Disability
Gadolinium Deposition Disease Symptoms Typically Begin Couple Of Months After Use And Can Continue For Many Years Without Any Diagnosis (Posted by Tom Lamb at DrugInjuryWatch.com) During MRI and MRA procedures patients…
-
DPP-4 Diabetes Drug Side Effects Include Heart Attacks And Strokes As Well As Heart Failure
Onglyza, Nesina, Januvia, and Tradjenta Are Included In This Popular Class Of Type-2 Diabetes Medications (Posted by Tom Lamb at DrugInjuryWatch.com) In April 2016 the FDA took regulatory action by mandating label…
-
Number Of Nuplazid Patient Deaths Reported To FDA In Just The Past Two Years Causes Alarm In Drug Safety Circles
This Relatively New Parkinson’s Disease Drug Already Been Implicated In Hundreds Of Death Cases, While Only Being On Market Since 2016 (Posted by Tom Lamb at DrugInjuryWatch.com) Two years ago the FDA…
